Preview

Медицинский Совет

Расширенный поиск

Возможности применения адеметионина у пациентов с неалкогольной жировой болезнью печени

https://doi.org/10.21518/2079-701X-2016-05-150-154

Полный текст:

Аннотация

В статье представлены данные по эпидемиологии, патогенезу, клиническим проявлениям, новым способам определения этиологии и фиброза, а также современные рекомендации по ведению пациентов с неалкогольной жировой болезнью печени (НАЖБП). Диета и физические упражнения остаются основным видом терапии при НАЖБП. Обсуждаются возможности применения адеметионина. Наиболее перспективной представляется разработка таргетных препаратов, направленных на подавление воспаления и фиброгенез. 

Об авторе

Л. Ю. Ильченко
Институт полиомиелита и вирусных энцефалитов ИПВЭ им. М.П. Чумакова, Москва
Россия
д.м.н., профессор


Список литературы

1. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med, 1999, 107: 450-455.

2. AGA Technical Review on Nonalcoholic Fatty Liver Disease. Gastroenterol., 2002, 123: 1705-1725.

3. Braunwald’s Heart Disease: A textbook of cardiovascular medicine, 7th ed. Saunders, 2011: 8-12.

4. Loomba R, Sanyal AJ. The global NAFLD epidemic. Rev Recent Clin Trials, 2014, 9: 126-133.

5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanya AJ. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatol., 2012, 55: 2005-2023.

6. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther., 2011, 34: 274-285.

7. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России. РЖГГК, 2014, 4: 32-38.

8. Harrison’sprinciples of internal medicine. 17th ed. NewYork: McGraw Hill, Medical Division, 2008. 1283 p.

9. Reaven GM. Role of Insulin Resistance in Human Disease. Diabetes, 1988, 37: 1595-1607.

10. Non-Alcoholic Fatty Liver Disease: A Practical Guide. Ed. GC Farrell, AJ McCullough, ChP Day. Wiley-Blackwell, 2013, 324 p.

11. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver dis￾ease. QJM, 2010, 103: 71-83.

12. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis, 2008, 28: 370-379.

13. Day CP, James OF. Steatohepatitis: a tale of two «hits»? Gastroenterol., 1998, 114: 842-845.

14. Roskams T, Yang SQ, Koteish A, Durnez A, DeVos R, Huang X, Achten R, Verslype C, Diehl AM. Oxida tive stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol., 2003, 163: 1301-1311.

15. Chan HL-Y, de Silva HJ, Leung NW-Y, Lim S-G, Farrell GC and the Asia-Pacific Working Party on NAFLD. How should we manage patients with nonalcoholic fatty liver disease in 2007? J Gastroenterol Hepatol, 2007, 22: 801-808.

16. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clinical Gastroenterol Hepatol, 2012, 10: 837-858.

17. Буеверов А.О. Многоликий стеатогепатит. Клин. перспект. гастроэнтерол. гепатол., 2012, 3: 3-9.

18. Moucari R, Chelbi E, Asselah T, Paradis V, Vidaud M, Cazals-Hatem D, Boyer N, Valla D, Marcellin P. Evidence for a Role of Nonalcoholic Steatohepatitis in Hepatitis C: A Prospective Study Pierre Bedossa. Hepatol., 2007, 46: 380-387.

19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steato￾hepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol, 1999, 94: 2467-2474.

20. Tiniakos DG, Kittas Ch. Pathology of nonalcoholic fatty liver disease. Annals Gastroenterol, 2005, 18: 148-159.

21. URL: http://www.mayoclinic.org/gi-rst/mayomodel10.html (Дата обращения: 04.03.2015).

22. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JD, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Thereau TM, Day CP. The NAFLD Fibrosis Score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatol, 2007, 45: 846-854.

23. Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic￾syndrome in nonalcoholic steatohepatitis. World J Gastroenterol, 2009, 15: 4387-4391.

24. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med, 2011, 43: 617-649.

25. Team R, LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh K-L, Hamid SS, Isakov V, Lizarzabal M, Pen˜aranda MM, Ramos JFR, Sarin S, Stimac D, Thomson ABR, Umar M, Krabshuis J, LeMair A. World Gastroenterology Organisation. Global Guidelines. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. J Clin Gastroenterol, 2014, 48: 467-473.

26. Preisig R. Supplements to the editorial «Liver protection therapy». Schweiz Rundsch Med Prax, 2007, 59: 1559-1560.

27. Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. 20th Anniversary Special Issues (12): Nonalcoholic fatty liver disease. World J Gastroenterol, 2014, 20: 16841-16857.

28. Kalhan SC, Edmison J, Marczewski S, Dasarathy S, Gruca LL, Bennett C, Duenas C, Lopez R. Methionine and protein metabolism in nonalcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clin Sci, 2011, 121: 179-189.

29. Mukherjee S. Betaine and nonalcoholic steatohepatitis: backto the future? World J Gastroenterol, 2011, 17: 3663-3664.

30. Mato JM, Camara J, Fernandez de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Beltrán J, Benita V, Caballería J, Solà R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Parés A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodés J. S-Adeno syl methionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol, 1999, 30: 1081-1089.

31. Ильченко Л.Ю., Винницкая Е.В. Пути метаболизма и применение гептрала при хронических заболеваниях печени. Экспер. клин. гастроэнтерол., 2002, 2: 62-64.

32. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J Hepatol., 2012, 57: 1097-1109.

33. Mato J.M., Luz Martinez-Chantar M., Lu Sh.C. S-adenosylmethionine metabolism and liver disease. Ann Hepatol, 2013, 12: 183-189.

34. Барановский А.Ю., Райхельсон К.Л., Марченко Н.В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клин. перспект. гастроэнтерол. гепатол., 2010, 1: 3-10.

35. Virukalpattigopalratnam MP, Singh T, Ravishankar AC. Heptral (ademetionine) in patients with intrahepatic cholestasis in chronic liver disease due to non-alcoholic liver disease: results of a multicentre observational study in India. J Indian Med Assoc., 2013, 111: 856-859.

36. URL: https://Clinicaltrials.gov (Дата обращения: 04.03.2015).


Просмотров: 73


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)